Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ABVC Abvc Biopharma Inc

Price (delayed)

$1.21

Market cap

$20.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.13

Enterprise value

$21.71M

Highlights
The gross margin has surged by 112% year-on-year
Abvc Biopharma's EPS has surged by 91% YoY and by 69% QoQ
The quick ratio has declined by 38% since the previous quarter and by 20% year-on-year
ABVC's equity is down by 31% year-on-year

Key stats

What are the main financial stats of ABVC
Market
Shares outstanding
16.77M
Market cap
$20.3M
Enterprise value
$21.71M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.91
Price to sales (P/S)
35.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.7
Earnings
Revenue
$508,384
Gross profit
$507,898
Operating income
-$1.95M
Net income
-$1.81M
EBIT
-$1.56M
EBITDA
-$1.24M
Free cash flow
-$1.88M
Per share
EPS
-$0.13
EPS diluted
-$0.13
Free cash flow per share
-$0.13
Book value per share
$0.42
Revenue per share
$0.03
TBVPS
$0.99
Balance sheet
Total assets
$14.88M
Total liabilities
$6.92M
Debt
$2.17M
Equity
$5.4M
Working capital
-$5.26M
Liquidity
Debt to equity
0.4
Current ratio
0.22
Quick ratio
0.2
Net debt/EBITDA
-1.13
Margins
EBITDA margin
-244.8%
Gross margin
99.9%
Net margin
-356.4%
Operating margin
-384.3%
Efficiency
Return on assets
-14.1%
Return on equity
-31.1%
Return on invested capital
-19.7%
Return on capital employed
-19.1%
Return on sales
-306.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABVC stock price

How has the Abvc Biopharma stock price performed over time
Intraday
-8.33%
1 week
15.24%
1 month
23.47%
1 year
10%
YTD
105.08%
QTD
14.15%

Financial performance

How have Abvc Biopharma's revenue and profit performed over time
Revenue
$508,384
Gross profit
$507,898
Operating income
-$1.95M
Net income
-$1.81M
Gross margin
99.9%
Net margin
-356.4%
The gross margin has surged by 112% year-on-year
The net margin has soared by 99% YoY and by 63% from the previous quarter
The operating margin has soared by 99% year-on-year and by 58% since the previous quarter
ABVC's net income has surged by 79% year-on-year and by 63% since the previous quarter

Price vs fundamentals

How does ABVC's price correlate with its fundamentals

Growth

What is Abvc Biopharma's growth rate over time

Valuation

What is Abvc Biopharma stock price valuation
P/E
N/A
P/B
2.91
P/S
35.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
42.7
Abvc Biopharma's EPS has surged by 91% YoY and by 69% QoQ
ABVC's equity is down by 31% year-on-year
The P/B is 8% more than the last 4 quarters average of 2.7
The P/S is 13% higher than the last 4 quarters average of 31.4

Efficiency

How efficient is Abvc Biopharma business performance
Abvc Biopharma's return on sales has surged by 99% YoY and by 63% QoQ
The company's return on equity has surged by 84% YoY and by 59% QoQ
The ROA has soared by 81% year-on-year and by 63% since the previous quarter
ABVC's ROIC has soared by 76% YoY and by 63% QoQ

Dividends

What is ABVC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABVC.

Financial health

How did Abvc Biopharma financials performed over time
ABVC's total assets is 115% greater than its total liabilities
ABVC's total assets has surged by 97% since the previous quarter and by 2.9% year-on-year
The quick ratio has declined by 38% since the previous quarter and by 20% year-on-year
The debt is 60% less than the equity
The debt to equity has dropped by 80% since the previous quarter but it has increased by 29% year-on-year
ABVC's equity is down by 31% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.